Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinic Acid/Laropiprant in Premature Ischemic Heart Disease with Elevated HDL-C
NCT01450410Phase 4Terminated
- Start
- Jul 2012
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of niacin and laropiprant in ischemic heart disease (IHD) and dyslipidemia (2 arms). Primary endpoint: Change in the apoA1 content associated to treatment at 12 weeks. Started Jul 2012; status: terminated.
02
Drugs
niacinlaropiprant
03
Conditions
ischemic heart disease (IHD)dyslipidemia
Beyond the preview
Go deeper on NCT01450410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01450410.